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Abstract
The purpose of this study was to evaluate the time-dependent probability and risk factors of pancreatogenic diabetes mellitus (PDM)
in patients who underwent minimally invasive subtotal distal pancreatectomy.
Changes in glucose metabolic consequence of 34 patients (laparoscopic: 31, robotic: 3) who underwent surgery from December
2005 to December 2014 were estimated by assessing impaired fasting glucose, PDM, and PDM-free time analysis.
A total of 22 patients showed glucose intolerance, including 13 (38.2%) with impaired fasting glucose and 9 (26.5%) with PDM. The
median onset time of PDM was 6.8 months (range 5.3–13.2 months). The PDM-free time probability according to time interval was
94.1% (6months), 75.9% (12months), and 72.6% (18months). It was shown that bodymass index>23kg/m2 (49.9 vs 87.9months,
P= .020) and preoperative cholesterol >200mg/dL (40.9 vs 85.2 months, P= .003) adversely inﬂuenced PDM-free time.
Preoperative cholesterol >200mg/dL (hazard ratio=6.172; 95% conﬁdence interval, 1.532–24.865; P= .010) was signiﬁcantly
associated with short PDM-free time in Cox proportional hazards model.
Patients with high cholesterol levels and high BMI should be closely monitored for the development of PDM.
Abbreviations: BMI = body mass index, DP = distal pancreatectomy, IFG = impaired fasting glucose, IGT = impaired glucose
tolerance, MI-STDP =minimally invasive STDP, PDM = pancreatogenic diabetes mellitus, POPF = postoperative pancreatic ﬁstula,
PPH = postpancreatectomy hemorrhage, SMV-SV-PV = superior mesenteric vein-splenic vein-portal vein, STDP = subtotal distal
pancreatectomy.
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When a tumor is detected in the neck or proximal body of the
pancreas, surgeons encounter the dilemma of whether to perform
central pancreatectomy or distal pancreatectomy (DP) with
division of the pancreatic neck, so-called subtotal distal
pancreatectomy (STDP). Central pancreatectomy is not frequent-Editor: Neil Merrett.
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1ly performed due to the risk of pancreatic ﬁstula resulting from
the 2 cut surfaces created by pancreatectomy, even though its
incidence of new-onset pancreatogenic diabetes mellitus (PDM) is
lower than that of STDP[1,2]. Therefore, most surgeons choose
to perform STDP when the tumor is located in the neck or
proximal body of the pancreas. However, removal of approxi-
mately 70% of pancreatic parenchyma by dividing the pancreas
neck is expected to result in high incidence of postoperative
new-onset PDM.
PDM is deﬁned as DM caused by diffuse destruction of the
pancreas, such as in pancreatic resection and chronic pancreatitis,
leading to deﬁciency in pancreatic hormones.[3] The American
Diabetes Association has categorized PDMas “other speciﬁc type
of diabetes mellitus-disease of the exocrine pancreas.”[4]
According to the literature, incidence of new-onset PDM after
partial pancreatectomy varies from 4% to 51%,[3,5–9] depending
on preexisting diseases, duration of follow-up period, and extent
of pancreatic resection. In addition, volume of remnant pancreas
after DP varies widely depending on location of tumor and
surgical method. Therefore, it is difﬁcult to identify the actual
incidence of new-onset PDM after DP.[5,10] In addition, the
incidence can vary based on time interval after surgery. Bruijin
et al[11] reported, in a systemic review, that within 6 months after
surgery, incidence of new-onset PDMwas 17%, which increased
to 36% after longer follow-up periods.
When performing STDP for benign or borderline pancreatic
tumors, a minimally invasive approach is feasible. According to
recent literatures, laparoscopic DP with or without splenectomy
has been accepted as a safe and effective treatment option for
Hwang et al. Medicine (2017) 96:51 Medicinebenign, borderline malignant, and even malignant pancreatic
tumors.[12–14] We recently described our technique of minimally
invasive STDP (MI-STDP),[15–17] and have been accumulating
long-term follow-up data. As incidence of new-onset PDM may
vary according to resected volume of the pancreas, we only
enrolled patients who underwent MI-STDP with the same
percentage of resected volume. We evaluated the overall
incidence of new-onset PDM and changes in glucose metabolic
consequence while focusing on the time interval after surgery.
This study can provide insight into long-term consequences to
glucose metabolism in patients with long life expectancies after
undergoing MI-STDP for benign and borderline tumors.2. Materials and methods
2.1. Patient selection
From December 2005 to December 2014, medical records of
patients who underwent MI-STDP (laparoscopic or robotic) by
dividing the neck of pancreas for benign or borderline tumors of
pancreas were retrospectively reviewed. As remnant volume and
percentage of the pancreas may vary in conventional DP
according to resected portion of pancreas, we excluded patients
who underwent DP less than a total neck, body, and tail resection
were performed. As open STDP was performed in most
malignant tumors and differences of surgical insults between
open and minimally invasive procedure might inﬂuence glucose
impairment after surgery, patients who underwent open STDP
were excluded. Patients who had preoperative diagnosis of DM
were also excluded. Over the study period, a total of 43 patients
underwent MI-STDP. Except for 9 patients who had diabetes
before surgery, 34 patients were included in this study. During the
ﬁrst 2 years after STDP, patients were regularly examined every 3
months, and then twice a year thereafter. Five years after
operation, patients were tested once a year. This retrospective
study was approved by the Institutional Review Board of Yonsei
University College of Medicine.2.2. Clinicopathological characteristics
This study evaluated perioperative clinicopathological variables
and follow-up data including the following: age, sex, body mass
index (BMI), tumor size, pathologic diagnosis, complications
such as postoperative pancreatic ﬁstula (POPF)[18] and post-
pancreatectomy hemorrhage (PPH),[19] 90-day mortality, length
of hospital stay, estimated blood loss, transfusion, fasting serum
albumin, cholesterol, glucose level, and HbA1c.Table 1
Pathologic diagnosis of the patients.
Diagnosis Frequency (%)
Solid pseudopapillary tumor 9 (26.5)
Mucinous cystic neoplasm 7 (20.6)
Intraductal papillary mucinous neoplasm 6 (17.6)
Chronic pancreatitis/pseudocyst 5 (14.7)
Pancreatic neuroendocrine tumor 4 (11.8)
Serous cystic neoplasm 3 (8.8)2.3. Deﬁnition of glucose metabolic consequences
Impaired fasting glucose (IFG) was deﬁned as a fasting serum
glucose level of 100 to 125mg/dL. Impaired glucose tolerance
(IGT) was not assessed in this retrospective study, as oral glucose
tolerance test was not administered to patients. According to the
American Diabetes Association criteria for diagnosis of DM,[4]
newly developed PDM after surgery was deﬁned when 2
consecutive follow-up blood laboratory tests fulﬁlled the
following criteria: fasting (no caloric intake for at least 8h)
serum glucose ≥126mg/dl, HbA1c >6.5%, or classic symptoms
of hyperglycemia or hyperglycemic crisis and a random serum
glucose ≥200mg/dL. As the probability of PDM changes are
based on the period of time after surgery, PDM-free time after
surgery was estimated by the Kaplan–Meier method.22.4. Surgical technique
We have described our technique for MI-STDP in previous
studies.[15–17] In brief, the whole pancreas is exposed after the
division of gastrocolic ligament, and a portion of pancreatic neck
is carefully dissected from the superior mesenteric vein-splenic
vein-portal vein (SMV-SV-PV) conﬂuence to create a window for
the division of pancreatic neck. Based on the tumor character-
istics, small individual tributary vessels were either preserved for
splenic vessel-conserving spleen-preserving STDP, or the entire
segments of both splenic vessels were excised with distal pancreas
for splenic vessel-sacriﬁcing spleen-preserving STDP. In cases
where spleen conservation was difﬁcult, combined splenectomy
was performed.2.5. Statistics
Continuous variables were described as mean± standard devia-
tion, and categorical variables were described as frequency (%).
In comparative analysis, Student t test and x2 test were applied.
PDM-free time was calculated using the Kaplan–Meier method,
and signiﬁcant difference between groups was assessed with a
log-rank test. Subsequently, Cox proportional hazards model
was applied for multivariate analysis to detect clinicopathological
factors predictive of impaired PDM-free time. Statistical analyses
were performed using SPSS 20.0 for Windows (SPSS Inc.,
Chicago, IL). P values <.05 were considered to be statistically
signiﬁcant.3. Results
3.1. Patient demographics
The average age of patients was 48±14 years. Twenty-eight
patients were female and 6 were male. Radiologic tumor size
was 3.6±2.1cm in maximal diameter, and pathological
diagnoses are listed in Table 1. Thirty patients (88.2%) either
retained their spleens by splenic vessels-conserving method
(20, 58.8%), or underwent segmental resection by splenic
vessels method (10, 29.4%). Operation time was 265±111
minutes, and intraoperative blood loss was estimated to be 240±
237mL. Only 1 patient required intraoperative transfusion.
Seven patients (20.6%) developed grade B POPF, and 1 patient
(2.9%) experienced grade C PPH requiring reoperation. PPH
developed when the closed suction drain was removed on
postoperative day 7. Metallic clip was released from the vessel
when drain was removed because the surgical metallic clip was
inserted into side hole of the drain. Length of hospital stay was
found to be 9±5 days. There was no 90-day mortality. Mean
duration of follow-up after surgery was 40.3 months (range 3.0–
97.1 months).
Figure 1. PDM-free time rate after MI-STDP. PDM-free time rates according to
time interval after surgery were 94.1% (6 months), 75.9% (12 months), and
72.6% (18 months).
Table 2
PDM-free time analysis after MI-STDP according to clinicopatho-
logic characteristics.
Univariate analysis
∗
Multivariate analysis†
Variables (n)
PDM-free
time
(mean), mo P HR
95%
conﬁdential
interval P
Age, y .057
45 (13) 90.1
>45 (21) 57.9
Sex .570
Female (28) 70.6
Male (6) 62.4
BMI, kg/m2 .020 .162
23 (20) 87.9
>23 (14) 49.9 3.263 0.621–17.145
Glucose (preop), mg/dL .520
90 (18) 72.0
>90 (16) 67.6
Cholesterol (preop), mg/dL .003 .010
200 (24) 85.2
>200 (10) 40.9 6.172 1.532–24.865
Chronic pancreatitis/pseudocyst .063
Yes (5) 14.9
No (29) 77.8
Tumor size, cm .237
3.6 (22) 65.9
>3.6 (12) 52.1
Surgical mode .679
Laparoscopic (31) 73.4
Robotic (3) 39.0
Spleen-preservation .807
No (4) 71.7
Yes (30) 72.9
POPF .283
No (27) 76.5
Yes (7) 37.5
BMI=body mass index, HR=hazards ratio, MI-STDP=minimally invasive subtotal distal
pancreatectomy, PDM=pancreatogenic diabetes mellitus, POPF=postoperative pancreatic ﬁstula,
Preop=preoperative.
∗
Kaplan–Meier analysis.
† Cox proportional hazards model.
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following MI-STDP
Preoperative serum fasting glucose concentration was observed
to be 91±8mg/dL. During the last follow-up period, ﬁnal
postoperative fasting glucose was found to be 113.1mL/dL,
which was signiﬁcantly higher than preoperative fasting glucose
level (P= .001). During the follow-up period, a total of 22
patients (64.7%) showed glucose intolerance, including 13
(38.2%) with IFG and 9 (26.5%) with PDM. All 9 patients
developed PDM within 24 months after surgery with a median
onset time of 6.8 months (range 5.3–13.2 months). PDM-free
time rates according to time interval after surgery were 94.1%
(6months), 75.9% (12months), and 72.6% (18months) (Fig. 1).
3.3. Clinicopathological factors inﬂuencing PDM-free time
It was shown that BMI >23kg/m2 (49.9 vs 87.9 months,
P= .020) and preoperative cholesterol >200mg/dL (40.9 vs 85.2
months, P= .003) adversely inﬂuenced PDM-free time over the
follow-up period (Table 2; Fig. 2). In particular, among 19
patients with both BMI 23kg/m2 and preoperative serum
cholesterol 200mg/dL, almost all of the patients (18 patients,
94.8%) were observed to be PDM-free (follow-up duration:
mean, 33.3 months with range, 6.3–97.1 months). For these
patients, last follow-up fasting serum glucose was 99±10mg/dL
and HbA1c was 5.8±0.2%.
Age >45 years (57.9 vs 90.1 months, P= .057) and chronic
pancreatitis/pseudocyst (14.9 vs 77.8 months, P= .063) were
marginally associated with shorter PDM-free time after MI-
STDP. However, other clinicopathological characteristics such as
sex, tumor size, surgical approach (laparoscopic vs robotic,
spleen preservation vs resection), preoperative fasting serum
glucose, operation time, and postoperative POPF were not
associated with PDM-free time after STDP (P > .05; Table 2).
3.4. Preoperative serum cholesterol >200mg/dL as
independent predictive factor for short PDM-free time
Cox proportional hazards model showed that preoperative
cholesterol >200mg/dL (hazard ratio=6.172; 95% conﬁdence3interval, 1.532–24.865; P= .010) was signiﬁcantly associated
with short PDM-free time after MI-STDP (Table 2). Older
patients (58±7 vs 45±14, P= .001) and those with high BMI
(25.3±4.0 vs 22.9±2.7, P= .045) were statistically associated
with preoperative serum cholesterol >200mg/dL (Table 3).4. Discussion
This study aimed to assess the overall percentage of new-onset
PDM and PDM-free time rate after MI-STDP, as well as to
evaluate the risk factors inﬂuencing PDM-free time. It has been
known that estimates of new-onset PDM after partial pancrea-
tectomy vary from 4% to 51%, since the incidence of PDM is
inﬂuenced by many factors such as the portion of pancreas
resected, total resected volume, duration of follow-up, and
preexisting diseases.[3,5–9]
When we focused on left-sided resection of the pancreas, the
resected volume had a wide range. If the resection margin was
located at the pancreas neck, which is known as STDP, the
resected volume could be >70%. Although incidences of new-
onset PDM after DP were reported to have wide range, no
existing study has yet investigated the incidence of new-onset
[20]
Figure 2. Inﬂuence of BMI and cholesterol level on PDM-free time. BMI>23kg/m2 (49.9 vs 87.9 months, P= .020) and preoperative cholesterol>200mg/dL (40.9
vs 85.2 months, P= .003) adversely inﬂuenced PDM-free time rate during follow-up period.
Hwang et al. Medicine (2017) 96:51 MedicinePDM limited to STDP. Sakata et al reported that resection of
>80% of the pancreas resulted in development of PDM in
approximately 67% of patients, and all patients developed new-
onset PDM if >90% of the pancreas was resected. Kang et al[21]
reported that endocrine functional impairment was 73.3% in
patients who underwent resection of >50% in volume of the
pancreas. In the present study, for STDP that had between 70%
and 80% resected volume of the pancreas, the incidence of new-
onset glucose impairment, including IFG and PDM, after STDP
was 64.7% (IFG: 38.2%, PDM: 26.5%). Our result of
investigating PDM after STDP did not show higher incidence
of PDM compared with conventional DP used in other studies.
Although resected volume of the pancreas in the development
of new-onset PDM is important, identiﬁcation of the underlying
disease is also important. In the systemic review by De Bruijin
et al,[11] the average cumulative incidence of new-onset PDM
after DP was higher in patients who underwent DP for chronic
pancreatitis than for benign or (potentially) malignant lesions
(39% vs 14%, P< .000). In this study, the incidence of new-onset
PDM in chronic pancreatitis/pseudocyst was higher than non-
chronic pancreatitis conditions (60% vs 20.7%, P= .102, data
was not shown). However, no statistically difference was
observed. In PDM-free time analysis, chronic pancreatitis/
pseudocyst (14.9 vs 77.8 months, P= .063) were marginally
associated with shorter PDM-free time after MI-STDP (Table 2).
As the rates of developing PDM after pancreatic resection can
vary according to time interval after pancreatectomy, a cross-
sectional assessment for incidence of PDM may fail to provide
enough information. Therefore, this study assessed PDM-free
time analysis using the Kaplan–Meier method and CoxTable 3
Clinical characteristics of patients with preoperative serum
cholesterol >200mg/dL.
Preoperative serum cholesterol, mg/dL
200 >200 P
Sex (female/male), n 19/5 9/1 .644
Age, y 45±14 58±7 .001
Preoperative serum glucose, mg/dL 91±9 91±8 .934
Body mass index, kg/m2 22.9±2.7 25.3±4.0 .045
Diagnosis (non-CP/CP), n 21/3 8/2 .618
Tumor size, cm 3.8±2.4 3.1±0.9 .273
Variables are expressed as the mean± standard deviation. CP= chronic pancreatitis, Non-CP=non-
chronic pancreatitis.
4proportional hazards model. In this study, all 9 patients who
developed PDM did so within 24 months after surgery with a
median onset time of 6.8months (range 5.3–13.2months). PDM-
free time was sustained until a mean of 72.7 month after STDP,
and 5-year serum glucose control was determined to be 72.6%.
Shirakawa et al[22] reported that the median onset time of PDM
after DP was 8 months (range 0.5–42 months). However, Kwon
et al[7] reported that the mean time interval of PDM after surgery
was 16.8months. In their study, all types of pancreatic resections,
including DP, central pancreatectomy, pylorus-preserving pan-
creaticoduodenectomy (PPPD), and pancreaticoduodenectomy
(PD), were included. Median-onset time of PDM after surgery
may be earlier in left-sided pancreatic resection than in PD or
PPPD. Pancreatic beta cells are concentrated in body and tail of
the pancreas. Therefore, left-sided pancreatic resection may
particularly predispose patients to develop PDM. In PD or PPPD,
remnant pancreas which is anastomosed with the jejunum or
stomach might develop atrophic changes. These morphologic
changes could result in later-onset PDM in patients who
underwent PD or PPPD, compared with those who underwent
left-sided pancreatectomy.
It is very important to identify the risk factors for PDM after
pancreatectomy, as these can inﬂuence the decision regarding but
the interval and length of follow-up for patients with benign and
borderline tumors with long life expectancy. IFG and IGT are
associated with obesity (especially abdominal or visceral obesity),
dyslipidemia with high triglycerides and/or low HDL, high
cholesterol, and hypertension.[4] In this study, it was shown that
BMI >23kg/m2 and preoperative cholesterol >200mg/dL
adversely inﬂuenced PDM-free time during follow-up period,
and that preoperative serum cholesterol >200mg/dL was
signiﬁcantly associated with short PDM-free time after MI-
STDP in multivariate analysis (Table 2; Fig. 2).
A euglycemic patient with obesity might develop overt DM
after pancreatic resection due to preoperative insulin resistance
and relative insulin deﬁciency.[3] In studies of Korean popula-
tions, BMI cutoff values of >20kg/m2[21] and 23.5kg/m2[7] have
been suggested as predictive of endocrine impairment after
pancreatic resection. In western countries, obesity is deﬁned as
BMI >30kg/m2. However, the International Association for the
Study of Obesity (IASO) and the International Obesity Task
Force (IOTF) have proposed a BMI cutoff value of 25kg/m2 for
obesity and 23 to 24.9kg/m2 for being overweight in Asian
populations.[23] Our result showed that BMI >23kg/m2 had an
adverse inﬂuence on the incidence of PDM during follow-up
period, and that patients with high BMI (25.3±4.0 vs 22.9±2.7,
[11] De Bruijn KM, van Eijck CH. New-onset diabetes after distal
Hwang et al. Medicine (2017) 96:51 www.md-journal.comP= .045) were statistically associated with preoperative serum
cholesterol >200mg/dL (Table 3).
In summary, when a tumor is located near the neck of the
pancreas, STDP offers the maximal extent of resection. When
preservation of a signiﬁcant amount of pancreatic volume is
impossible, surgeons should consider the risk of PDM before
surgery. Patients with high BMI and high cholesterol levels, with
benign and borderline malignant lesions of the pancreas, should
be closely monitored for development of PDM over a long period
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